These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 19880354)

  • 1. Duodenal complications in radiotherapy for bile duct cancer: a dose-volume histogram analysis.
    Nakamura R; Kato K; Sone M; Oikawa H; Ehara S
    Brachytherapy; 2010; 9(1):71-5. PubMed ID: 19880354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.
    Milano MT; Chmura SJ; Garofalo MC; Rash C; Roeske JC; Connell PP; Kwon OH; Jani AB; Heimann R
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):445-53. PubMed ID: 15145161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy doses at special reference points correlate with the outcome of cervical cancer therapy.
    Yoshimura R; Hayashi K; Ayukawa F; Toda K; Iwata M; Oota S; Hoshi A; Wakatsuki M; Kurosaki H; Okazaki A; Shibuya H
    Brachytherapy; 2008; 7(3):260-6. PubMed ID: 18579445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
    Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Broadwater G; Anscher MS; Chino JP; Oleson JR
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):139-46. PubMed ID: 19836161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy.
    Buyyounouski MK; Horwitz EM; Uzzo RG; Price RA; McNeeley SW; Azizi D; Hanlon AL; Milestone BN; Pollack A
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1383-91. PubMed ID: 15275723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers--preliminary results.
    Narayana A; Cohen GN; Zaider M; Chan K; Lee N; Wong RJ; Boyle J; Shaha A; Kraus D; Shah J; Zelefsky MJ
    Brachytherapy; 2007; 6(2):157-63. PubMed ID: 17434110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment.
    Buyyounouski MK; Horwitz EM; Price RA; Hanlon AL; Uzzo RG; Pollack A
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):743-9. PubMed ID: 14967429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study in the treatment of endometrial carcinoma with 3D image-based high-dose-rate brachytherapy using modified Heyman packing: clinical experience and dose-volume histogram analysis.
    Weitmann HD; Pötter R; Waldhäusl C; Nechvile E; Kirisits C; Knocke TH
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):468-78. PubMed ID: 15890589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anal wall sparing effect of an endorectal balloon in 3D conformal and intensity-modulated prostate radiotherapy.
    Smeenk RJ; van Lin EN; van Kollenburg P; Kunze-Busch M; Kaanders JH
    Radiother Oncol; 2009 Oct; 93(1):131-6. PubMed ID: 19523704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect.
    Zapatero A; García-Vicente F; Modolell I; Alcántara P; Floriano A; Cruz-Conde A; Torres JJ; Pérez-Torrubia A
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1343-51. PubMed ID: 15275719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chest wall dose in MammoSite breast brachytherapy: radiobiologic estimations of late complication risk based on dose-volume considerations.
    Dragun AE; Aguero EG; Harmon JF; Harper JL; Jenrette JM
    Brachytherapy; 2005; 4(4):259-63. PubMed ID: 16344255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical comparison of two linear-quadratic model-based isoeffect fractionation schemes of high-dose-rate intracavitary brachytherapy for cervical cancer.
    Wang CJ; Huang EY; Sun LM; Chen HC; Fang FM; Hsu HC; Changchien CC; Leung SW
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):179-89. PubMed ID: 15093915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.